However, BC-specific mortality risks were elevated among women with ER+/PR−, ER−/PR+, and ER−/PR− tumors relative to women with ER+/PR+ tumors across all subcategories of age cancer diagnosis [20, 21]. Here, ESR1 is linked to cancer.